This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chandrasekar, B. Articles by Tanguay, J.-F. Search for Related Content PubMed PubMed Citation Articles by Chandrasekar, B. Articles by Tanguay, J.-F.

EXPERIMENTAL STUDY

Local delivery of 17-beta-estradiol decreases neointimal hyperplasia after coronary angioplasty in a porcine model

^a Department of Medicine, Montreal Heart Institute and University of Montreal, Montreal, Quebec, Canada

Manuscript received October 26, 1999; revised manuscript received May 17, 2000, accepted July 12, 2000.

Reprint requests and correspondence: Dr. Jean-François Tanguay, Montreal Heart Institute, Research Center, 5000 Belanger Street East, Montreal, Quebec, Canada H1T 1C8
tanguay{at}icm.umontreal.ca

BACKGROUND

Neointimal hyperplasia is an important mechanism of restenosis after percutaneous transluminal coronary angioplasty (PTCA). Systemically administered estrogen is known to inhibit neointimal formation after arterial injury.

OBJECTIVES

We sought to assess the efficacy of locally delivered 17-beta-estradiol (BE) in inhibiting neointimal hyperplasia after PTCA.

METHODS

Eighteen juvenile farm pigs were studied. Coronary angioplasty was performed in all three coronary arteries of each animal. After PTCA, each coronary artery in each pig was randomized to receive either local delivery of 600 µg BE, vehicle alone or PTCA only. Twelve animals were euthanized at 28 days for morphometric analysis, and four animals were euthanized at seven days for immunohistochemical analysis of vascular smooth muscle cell (SMC) proliferative activity. Two animals died a few days after PTCA and were excluded.

RESULTS

On morphometric study, the arterial segments treated with BE demonstrated significantly less neointimal proliferation. Arteries treated with BE had reductions in several indexes of restenosis compared with arteries treated with vehicle alone or PTCA only: neointimal area (0.4 ± 0.09 mm² for BE vs. 1.14 ± 0.33 mm² for vehicle alone vs. 0.88 ± 0.2 mm² for PTCA only, p < 0.05), percent neointima (12.16 ± 2.57% vs. 25.46 ± 4.73% vs. 23.02 ± 3.97%, p < 0.025), neointima/media area (0.59 ± 0.14 vs. 1.75 ± 0.41 vs. 1.67 ± 0.43, p < 0.01) and restenotic index (1.3 ± 0.14 vs. 2.42 ± 0.22 vs. 2.4 ± 0.23, p < 0.005). Immunohistochemistry showed decreased SMC proliferative activity in BE-treated arteries compared with the other two treatment groups (p < 0.05).

CONCLUSIONS

Local delivery of BE significantly decreases neointimal hyperplasia after PTCA in pigs, probably by the inhibition of SMC proliferation.

Abbreviations and Acronyms   BE = 17-beta-estradiol   EEL = external elastic lamina   FL = fracture length   HPCD = 2-hydroxypropyl-beta-cyclodextrin   IEL = internal elastic lamina   PCNA = proliferating cell nuclear antigen   PTCA = percutaneous transluminal coronary angioplasty   SMC = smooth muscle cell

This article has been cited by other articles:

				I. C Villar, A. J Hobbs, and A. Ahluwalia Sex differences in vascular function: implication of endothelium-derived hyperpolarizing factor J. Endocrinol., June 1, 2008; 197(3): 447 - 462. [Abstract] [Full Text] [PDF]

				C. Filipe, L. Lam Shang Leen, L. Brouchet, A. Billon, V. Benouaich, V. Fontaine, P. Gourdy, F. Lenfant, J.-F. Arnal, A.-P. Gadeau, et al. Estradiol accelerates endothelial healing through the retrograde commitment of uninjured endothelium Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2822 - H2830. [Abstract] [Full Text] [PDF]

				T. Adriaenssens, J. Mehilli, R. Wessely, G. Ndrepepa, M. Seyfarth, A. Wieczorek, B. Blaich, R. Iijima, J. Pache, A. Kastrati, et al. Does Addition of Estradiol Improve the Efficacy of a Rapamycin-Eluting Stent?: Results of the ISAR-PEACE Randomized Trial J. Am. Coll. Cardiol., March 27, 2007; 49(12): 1265 - 1271. [Abstract] [Full Text] [PDF]

				Y. D. Krom, N. M.M. Pires, J. W. Jukema, M. R. de Vries, R. R. Frants, L. M. Havekes, K. W. van Dijk, and P. H.A. Quax Inhibition of neointima formation by local delivery of estrogen receptor alpha and beta specific agonists Cardiovasc Res, January 1, 2007; 73(1): 217 - 226. [Abstract] [Full Text] [PDF]

				A. Abizaid, M. Albertal, M. A. Costa, A. S. Abizaid, R. Staico, F. Feres, L. A. Mattos, A. G. M. R. Sousa, J. Moses, N. Kipshidize, et al. First human experience with the 17-beta-estradiol-eluting stent: The estrogen and stents to eliminate restenosis (EASTER) trial J. Am. Coll. Cardiol., March 17, 2004; 43(6): 1118 - 1121. [Abstract] [Full Text] [PDF]

				P. Geraldes, M. G. Sirois, and J.-F. Tanguay Specific Contribution of Estrogen Receptors on Mitogen-Activated Protein Kinase Pathways and Vascular Cell Activation Circ. Res., September 5, 2003; 93(5): 399 - 405. [Abstract] [Full Text] [PDF]

				P. Geraldes, M. G. Sirois, P. N. Bernatchez, and J.-F. Tanguay Estrogen Regulation of Endothelial and Smooth Muscle Cell Migration and Proliferation: Role of p38 and p42/44 Mitogen-Activated Protein Kinase Arterioscler. Thromb. Vasc. Biol., October 1, 2002; 22(10): 1585 - 1590. [Abstract] [Full Text] [PDF]

				B. Chandrasekar, S. Nattel, and J.-F. Tanguay Coronary artery endothelial protection after local delivery of 17{beta}-estradiol during balloon angioplasty in a porcine model: a potential new pharmacologic approach to improve endothelial function J. Am. Coll. Cardiol., November 1, 2001; 38(5): 1570 - 1576. [Abstract] [Full Text] [PDF]